The deubiquitinating enzyme USP15 stabilizes ERα and promotes breast cancer progression.
Ontology highlight
ABSTRACT: Breast cancer has the highest incidence and mortality in women worldwide. There are 70% of breast cancers considered as estrogen receptor α (ERα) positive. Therefore, the ERα-targeted therapy has become one of the most effective solution for patients with breast cancer. Whereas a better understanding of ERα regulation is critical to shape evolutional treatments for breast cancer. By exploring the regulatory mechanisms of ERα at levels of post-translational modifications, we identified the deubiquitinase USP15 as a novel protector for preventing ERα degradation and a critical driver for breast cancer progression. Specifically, we demonstrated that USP15 promoted the proliferation of ERα+, but not ERα- breast cancer, in vivo and in vitro. Meanwhile, USP15 knockdown nota
SUBMITTER: Xia X
PROVIDER: S-EPMC7997968 | biostudies-literature | 2021 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA